文献速递心力衰竭与心肌病心律失常

非奈利酮在心力衰竭合并房颤患者中的疗效与安全性:FINEARTS-HF 随机临床试验二次分析

Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究基于 FINEARTS-HF 随机临床试验,在 5984 例射程分数轻度降低或保留的心衰患者中,预设分析非奈利酮的疗效与安全性是否受基线房颤状态及房颤类型影响。新发房颤/房扑与后续主要终点风险显著升高相关。

要点

  • 新发房颤/房扑与后续主要终点调整后风险比 3.65(95%CI 2.57-5.18)相关。

核心结论

  • 非奈利酮在射程分数轻度降低或保留的心衰患者中的疗效不受基线房颤状态影响。
  • 新发房颤/房扑与后续主要终点风险显著升高相关。

研究设计与样本

  • FINEARTS-HF 随机临床试验的预设二次分析,覆盖 37 个国家 653 个中心。
  • 纳入 5984 例年龄≥40 岁、有症状且左室射血分数≥40% 的心衰患者,基线房颤状态已知。
  • 患者随机接受非奈利酮(滴定至 20 mg 或 40 mg)或安慰剂,随机时间 2020 年 9 月至 2023 年 1 月。

主要发现

  • 基线时 1384 例(23.1%)为阵发性房颤,1886 例(31.5%)为持续性或永久性房颤,2714 例(45.4%)无房颤。
  • 与无房颤相比,阵发性房颤和持续性/永久性房颤的未调整主要终点事件率分别为 20.3(95%CI 17.9-23.1)和 19.8(95%CI 17.8-22.0)每 100 人年,无房颤为 11.9(95%CI 10.7-13.3)。
  • 未调整率比:阵发性房颤 vs 无房颤为 1.62(95%CI 1.37-1.92),持续性/永久性房颤 vs 无房颤为 1.66(95%CI 1.43-1.93),校正已知预后变量后关联减弱。

临床怎么用

  • 对于射程分数轻度降低或保留的心衰患者,无论基线是否存在房颤或房颤类型,均可考虑使用非奈利酮。
  • 新发房颤/房扑提示后续心衰事件或心血管死亡风险显著升高,需加强监测与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Heart failure (HF) with mildly reduced or preserved ejection fraction and atrial fibrillation (AF) are closely intertwined. OBJECTIVE: To examine the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with HF with mildly reduced or preserved ejection fraction according to the absence or presence of AF and the type of AF (paroxysmal vs persistent or permanent). DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial. The trial was conducted across 653 sites in 37 countries. Participants were adults aged 40 years and older with symptomatic HF and left ventricular ejection fraction of 40% or greater, randomized between September 2020 and January 2023. Data analysis was conducted from September 1 to October 1, 2024. INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of total HF events and cardiovascular death. New-onset AF or atrial flutter (AFL) was a prespecified exploratory outcome. RESULTS: Among 5984 patients (mean [SD] age, 72.0 [9.6] years; 2724 [45.5%] female) with known AF status at baseline, 1384 (23.1%) had paroxysmal AF and 1886 (31.5%) had persistent or permanent AF. Patients with both types of AF were older and had worse HF status compared with those without AF (2714 patients [45.4%]). Both types of AF were associated with a higher unadjusted risk of the primary outcome compared with no AF (event rate per 100 person-years of follow-up, 20.3 [95% CI, 17.9-23.1] with paroxysmal AF, 19.8 [95% CI, 17.8-22.0] with persistent or permanent AF, and 11.9 [95% CI, 10.7-13.3] with no AF; rate ratio [RR], 1.62 [95% CI, 1.37-1.92] with paroxysmal AF and 1.66 [95% CI, 1.43-1.93] with persistent or permanent AF vs no AF); however, the associations were attenuated after adjustment for known prognostic variables. The benefit of finerenone on the primary outcome (overall RR, 0.84 [95% CI, 0.74-0.95]) was not modified by baseline AF status (RR, 0.80 [95% CI, 0.65-0.98] with no AF, 0.83 [95% CI, 0.65-1.06] with paroxysmal AF, and 0.85 [95% CI, 0.69-1.05] with persistent or permanent AF; P for interaction = .94). New-onset AF or AFL occurred in 6.5% of patients and was associated with a higher subsequent adjusted risk of the primary outcome (rate ratio, 3.65 [95% CI, 2.57-5.18]; P < .001). The subdistribution hazard ratio for new-onset AF or AFL among those receiving finerenone vs placebo was 0.77 (95% CI, 0.57-1.04; P = .09). CONCLUSIONS AND RELEVANCE: The efficacy of finerenone was consistent regardless of AF status. New-onset AF was associated with a substantially higher risk of subsequent outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Matsumoto, Henderson, Jhund, et al. Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 40156827. doi:10.1001/jamacardio.2025.0848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。